Ccr5 and Cxcr2 promote pancreatic cancer progression30,31 and metastasis (in the case of Cxcr2), and their chemical inhibition has been proposed as cancer immunotherapy32,33. This evidence concerns the gene CCR5 and pancreatic neoplasm.